Corbus Pharmaceuticals (CRBP)
NASDAQ:CRBP
Want to see CRBP full AI Analyst Report?
CRBP Stock Chart & Stats
$10.59
-$0.10(-0.79%)
At close: 4:00 PM EST
$10.59
-$0.10(-0.79%)
Day’s Range― - ―
52-Week Range$6.72 - $20.56
Previous CloseN/A
Volume39.58K
Average Volume (3M)503.64K
Market Cap
$141.55M
Enterprise Value$74.31M
Total Cash (Recent Filing)$138.60M
Total Debt (Recent Filing)$1.21M
Price to Earnings (P/E)―
Beta1.62
Next Earnings
Aug 11, 2026EPS Estimate
-1.26Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-6.31
Shares Outstanding18,527,796
10 Day Avg. Volume744,820
30 Day Avg. Volume503,638
Financial Highlights & Ratios
PEG Ratio-0.02
Price to Book (P/B)0.73
Price to Sales (P/S)0.00
P/FCF Ratio-1.68
Enterprise Value/Market Cap0.52
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit-498.76
Enterprise Value/Ebitda-0.87
Forecast
1Y Price Target
$38.67Price Target Upside265.12% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering10
EPS Forecast (FY)-4.64
Revenue Forecast (FY)$1.67M
Bulls Say, Bears Say
Bulls Say
FDA Alignment For CRB-701 Registrational PathRegulatory alignment materially lowers execution risk for late-stage development: clear endpoints (ORR for potential accelerated approval, OS for full approval) and single randomized trial designs enable definitive protocol planning, faster trial starts (summer 2026) and a more predictable route to approval if efficacy is confirmed.
Strong Balance Sheet And Low LeverageVery low leverage and sizeable equity position provide financial flexibility to fund registrational trials and ongoing R&D without immediate reliance on debt. Reported cash runway into 2028 reduces near-term dilution pressure and supports multi-program development through key 2026–2028 milestones.
Promising CRB-701 Efficacy And TolerabilityHigh objective response rates, durability and tolerability in HPV-driven tumors position CRB-701 as a differentiated ADC candidate. Biomarker links (Nectin-4, HPV positivity) and low discontinuation rates support targeted patient selection, improving the odds of registrational success and future commercial differentiation if pivotal trials confirm benefit.
Bears Say
Pre-revenue With Widening LossesThe absence of product revenue and materially larger net losses reflect a classic pre-commercial biotech profile that depends on capital markets. Persistent negative profitability erodes equity over time and means the company must convert clinical success into commercialization or recurring partnership revenue to achieve sustainable economics.
High Operating And Free Cash Flow BurnSubstantial negative operating and free cash flows increase the probability of future equity raises or partnering, which can dilute shareholders and shift program priorities. Large cash burn constrains strategic optionality across oncology and obesity programs if clinical timelines slip or costs accelerate.
CMO Resignation During Registrational TransitionLosing the CMO while moving CRB-701 into registrational trials creates execution risk: continuity in trial design, regulatory interactions and operational oversight may be disrupted. Recruiting an experienced replacement can take months and divert management attention during a critical development phase.
Corbus Pharmaceuticals News
CRBP FAQ
What was Corbus Pharmaceuticals’s price range in the past 12 months?
Corbus Pharmaceuticals lowest stock price was $6.72 and its highest was $20.56 in the past 12 months.
What is Corbus Pharmaceuticals’s market cap?
Corbus Pharmaceuticals’s market cap is $141.55M.
When is Corbus Pharmaceuticals’s upcoming earnings report date?
Corbus Pharmaceuticals’s upcoming earnings report date is Aug 11, 2026 which is in 72 days.
How were Corbus Pharmaceuticals’s earnings last quarter?
Corbus Pharmaceuticals released its earnings results on May 12, 2026. The company reported -$1.23 earnings per share for the quarter, missing the consensus estimate of -$1.221 by -$0.009.
Is Corbus Pharmaceuticals overvalued?
According to Wall Street analysts Corbus Pharmaceuticals’s price is currently Undervalued.
Does Corbus Pharmaceuticals pay dividends?
Corbus Pharmaceuticals does not currently pay dividends.
What is Corbus Pharmaceuticals’s EPS estimate?
Corbus Pharmaceuticals’s EPS estimate is -1.26.
How many shares outstanding does Corbus Pharmaceuticals have?
Corbus Pharmaceuticals has 18,527,796 shares outstanding.
What happened to Corbus Pharmaceuticals’s price movement after its last earnings report?
Corbus Pharmaceuticals reported an EPS of -$1.23 in its last earnings report, missing expectations of -$1.221. Following the earnings report the stock price went up 3.533%.
Which hedge fund is a major shareholder of Corbus Pharmaceuticals?
Currently, no hedge funds are holding shares in CRBP
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Corbus Pharmaceuticals Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$38.67 (265.12% Upside)
$38.67 (265.12% Upside)
Hedge Fund Trend
Decreased
By 15.4K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $50.5K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Positive
Last 7 Days ▲ 19.5%
Last 30 Days ▲ 33.0%
Last 30 Days ▲ 33.0%
News Sentiment
Very Bullish
Bullish news 90%
Bearish news 10%
Bearish news 10%
Technicals
SMA
Positive
20 days / 200 days
Momentum
-43.19%
12-Months-Change
Fundamentals
Return on Equity
-70.89%
Trailing 12-Months
Asset Growth
3.25%
Trailing 12-Months
Company Description
Corbus Pharmaceuticals
Corbus Pharmaceuticals Holdings, Inc., a biopharmaceutical company, focuses on the development of immune modulators for immuno-oncology and fibrosis diseases. It develops lenabasum, an oral molecule that selectively activates cannabinoid receptor type 2 (CB2), which is in Phase II clinical trial to treat systemic lupus erythematosus; CRB-601, an anti-integrin monoclonal antibody (mAb) for the treatment of cancer and fibrosis that inhibits the activation of transforming growth factor ß (TGFß); and CRB-602, an anti-avß6/avß8 mAb that blocks the activation of TGFß for the treatment of fibrotic diseases. The company is also developing cannabinoid receptor type 1 inverse agonist program for the treatment of metabolic disorders, such as obesity, diabetic nephropathy, diabetic retinopathy, and nonalcoholic steatohepatitis; fibrotic diseases, including lung, cardiac, renal disease, and liver fibrosis; and other diseases comprising ascites, cognitive defects, Prader-Willi syndrome, and smoking cessation. It has a licensing agreement with Jenrin Discovery, LLC to develop and commercialize the licensed products, including the Jenrin library of approximately 600 compounds, and multiple issued and pending patent filings. The company was incorporated in 2009 and is based in Norwood, Massachusetts.
CRBP Stock 12 Month Forecast
Average Price Target
$38.67
▲(265.12% Upside)
Technical Analysis
Ownership Overview
15.61% Insiders
5.18% Mutual Funds
39.74% Other Institutional Investors
33.86% Public Companies and
Individual Investors